Short Interest in Geron Expands By 4.4% (GERN)
Shares of Geron (NASDAQ:GERN) were the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 24,897,878 shares, a growth of 4.4% from the July 31st total of 23,848,526 shares, Stock Ratings Network reports. Currently, 16.0% of the shares of the company are sold short. Based on an average daily trading volume, of 2,221,673 shares, the days-to-cover ratio is currently 11.2 days.
GERN has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Geron in a research note on Tuesday, August 26th. They now have a $2.50 price target on the stock. Analysts at MLV & Co
upgraded shares of Geron from a “hold” rating to a “buy” rating in a research note on Thursday, June 12th. They now have a $4.25 price target on the stock, up previously from $2.00. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Geron has an average rating of “Hold” and an average target price of $3.38.
Shares of Geron (NASDAQ:GERN) opened at 2.38 on Monday. Geron has a one year low of $1.3138 and a one year high of $7.3629. The stock’s 50-day moving average is $2.45 and its 200-day moving average is $2.56. The company’s market cap is $373.4 million.
Geron (NASDAQ:GERN) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.06). The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.22 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s quarterly revenue was up 209.1% on a year-over-year basis. On average, analysts predict that Geron will post $-0.23 earnings per share for the current fiscal year.
Geron Corporation (NASDAQ:GERN) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.